Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the Tumor-targeting Human L19IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer

NCT01198522 is registered in ClinicalTrials.gov with Philogen S.p.A. as lead sponsor.

NCT NCT01198522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01198522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the Tumor-targeting Human L19IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer
Lead sponsor
Philogen S.p.A.
Phase
Phase 1
Overall status
Terminated
Start date
June 30, 2007
Completion date
November 30, 2014
Enrollment
28 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer patients diagnosed with locally advanced or metastatic pancreatic cancer not amenable to curative surgical resection